27782940|t|Effects of Obesity and Leptin Deficiency on Morphine Pharmacokinetics in a Mouse Model
27782940|a|Obesity causes multiorgan dysfunction, specifically metabolic abnormalities in the liver. Obese patients are opioid - sensitive and have high rates of respiratory complications after surgery. Obesity also has been shown to cause resistance to leptin, an adipose -derived hormone that is key in regulating hunger, metabolism, and respiratory stimulation. We hypothesized that obesity and leptin deficiency impair opioid pharmacokinetics (PK) independently of one another. Morphine PK were characterized in C57BL/6J wild-type (WT), diet-induced obese (DIO), and leptin-deficient (ob/ob) mice, and in ob/ob mice given leptin-replacement (LR) therapy. WT mice received several dosing regimens of morphine. Obese mice (30 g) received one 80 mg/kg bolus of morphine. Blood was collected at fixed times after morphine injection for quantification of plasma morphine and morphine 3-glucuronide (M3G) levels. PK parameters used to evaluate morphine metabolism included area-under the curve (AUC150), maximal morphine concentration (CMAX), and M3G -to- morphine ratio, and drug elimination was determined by clearance (Cl/F), volume of distribution, and half-life (T1/2). PK parameters were compared between mouse groups by the use of 1-way analysis of variance, with P values less than .05 considered significant. DIO compared with WT mice had significantly decreased morphine metabolism with lower M3G -to- morphine ratio (mean difference [MD]: -4.9; 95% confidence interval [CI]: -8.8 to -0.9) as well as a decreased Cl/F (MD: -4.0; 95% CI: -8.9 to -0.03) Ob/ob compared with WT mice had a large increase in morphine exposure with a greater AUC150 (MD: 980.4; 95% CI: 630.1-1330.6), CMAX (MD: 6.8; 95% CI: 2.7-10.9), and longer T1/2 (MD: 23.1; 95% CI: 10.5-35.6), as well as a decreased Cl/F (MD: -7.0; 95% CI: -11.6 to -2.7). Several PK parameters were significantly greater in ob/ob compared with DIO mice, including AUC150 (MD: 636.4; 95% CI: 207.4-1065.4), CMAX (MD: 5.3; 95% CI: 3.2-10.3), and T1/2 (MD: 18.3; 95% CI: 2.8-33.7). When leptin was replaced in ob/ob mice, PK parameters began to approach DIO and WT levels. LR compared with ob/ob mice had significant decreases in AUC150 (MD: -779.9; 95% CI: -1229.8 to -330), CMAX (MD: -6.1; 95% CI: -11.4 to -0.9), and T1/2 (MD: -19; 95% CI: -35.1 to -2.8). Metabolism increased with LR, with LR mice having a greater M3G -to- morphine ratio compared with DIO (MD: 5.3; 95% CI: 0.3-10.4). Systemic effects associated with obesity decrease morphine metabolism and excretion. A previous study from our laboratory demonstrated that obesity and leptin deficiency decrease the sensitivity of central respiratory control centers to carbon dioxide. Obesity and leptin deficiency substantially decreased morphine metabolism and clearance, and replacing leptin attenuated the PK changes associated with leptin deficiency, suggesting leptin has a direct role in morphine metabolism.
27782940	0	10	Effects of	T080	C1704420
27782940	11	18	Obesity	T047	C0028754
27782940	23	40	Leptin Deficiency	T047	C3554224
27782940	44	52	Morphine	T109,T121	C0026549
27782940	53	69	Pharmacokinetics	T039	C0031327
27782940	75	86	Mouse Model	T050	C2986594
27782940	87	94	Obesity	T047	C0028754
27782940	95	101	causes	T169	C0015127
27782940	102	124	multiorgan dysfunction	T046	C0026766
27782940	139	162	metabolic abnormalities	T033	C1704258
27782940	170	175	liver	T023	C0023884
27782940	177	182	Obese	T047	C0028754
27782940	183	191	patients	T101	C0030705
27782940	196	202	opioid	T109,T121,T131	C0242402
27782940	205	214	sensitive	T169	C0332324
27782940	229	234	rates	T081	C1521828
27782940	238	263	respiratory complications	T046	C0161818
27782940	270	277	surgery	T061	C0543467
27782940	279	286	Obesity	T047	C0028754
27782940	316	326	resistance	T169	C4281815
27782940	330	336	leptin	T116,T125	C0299583
27782940	341	348	adipose	T024	C0001527
27782940	358	365	hormone	T125	C0019932
27782940	381	391	regulating	T038	C1327622
27782940	392	398	hunger	T184	C0020175
27782940	400	410	metabolism	T040	C0025519
27782940	416	427	respiratory	T169	C0521346
27782940	428	439	stimulation	T044	C0038337
27782940	462	469	obesity	T047	C0028754
27782940	474	491	leptin deficiency	T047	C3554224
27782940	499	505	opioid	T109,T121,T131	C0242402
27782940	506	522	pharmacokinetics	T039	C0031327
27782940	524	526	PK	T039	C0031327
27782940	558	566	Morphine	T109,T121	C0026549
27782940	567	569	PK	T039	C0031327
27782940	575	588	characterized	T052	C1880022
27782940	592	600	C57BL/6J	T015	C1516103
27782940	601	610	wild-type	T015	C1520150
27782940	612	614	WT	T015	C1520150
27782940	617	641	diet-induced obese (DIO)	T015	C0025933
27782940	647	676	leptin-deficient (ob/ob) mice	T015	C0025933
27782940	685	695	ob/ob mice	T015	C0025933
27782940	702	733	leptin-replacement (LR) therapy	T061	C0282402
27782940	735	742	WT mice	T015	C1520150
27782940	767	775	regimens	T170	C2945654
27782940	779	787	morphine	T109,T121	C0026549
27782940	789	799	Obese mice	T015	C0025933
27782940	807	815	received	T080	C1514756
27782940	829	846	bolus of morphine	T109,T121	C0026549
27782940	848	853	Blood	T031	C0005767
27782940	858	867	collected	T078	C1516695
27782940	877	882	times	T081	C1632851
27782940	889	897	morphine	T109,T121	C0026549
27782940	898	907	injection	T061	C0021485
27782940	912	926	quantification	T081	C1709793
27782940	930	936	plasma	T031	C0032105
27782940	937	945	morphine	T109,T121	C0026549
27782940	950	978	morphine 3-glucuronide (M3G)	T109,T121	C0066815
27782940	979	985	levels	T080	C0441889
27782940	987	989	PK	T039	C0031327
27782940	990	1000	parameters	T033	C0449381
27782940	1009	1017	evaluate	T058	C0220825
27782940	1018	1026	morphine	T109,T121	C0026549
27782940	1027	1037	metabolism	T040	C0025519
27782940	1047	1067	area-under the curve	T081	C0376690
27782940	1069	1075	AUC150	T081	C0376690
27782940	1086	1094	morphine	T109,T121	C0026549
27782940	1095	1108	concentration	T081	C0678756
27782940	1110	1114	CMAX	T081	C2347813
27782940	1121	1124	M3G	T109,T121	C0066815
27782940	1130	1138	morphine	T109,T121	C0026549
27782940	1139	1144	ratio	T081	C0456603
27782940	1150	1166	drug elimination	T040	C0683141
27782940	1185	1194	clearance	T201	C1382187
27782940	1196	1200	Cl/F	T201	C1382187
27782940	1203	1225	volume of distribution	T081	C0683148
27782940	1231	1240	half-life	T079	C0018517
27782940	1242	1246	T1/2	T079	C0018517
27782940	1249	1251	PK	T039	C0031327
27782940	1252	1262	parameters	T033	C0449381
27782940	1285	1290	mouse	T015	C0025929
27782940	1291	1297	groups	T078	C0441833
27782940	1312	1338	1-way analysis of variance	T081	C0002780
27782940	1345	1353	P values	T081	C0033204
27782940	1379	1390	significant	T078	C0750502
27782940	1392	1395	DIO	T015	C0025933
27782940	1410	1417	WT mice	T015	C1520150
27782940	1422	1435	significantly	T078	C0750502
27782940	1436	1445	decreased	T081	C0205216
27782940	1446	1454	morphine	T109,T121	C0026549
27782940	1455	1465	metabolism	T040	C0025519
27782940	1477	1480	M3G	T109,T121	C0066815
27782940	1486	1494	morphine	T109,T121	C0026549
27782940	1495	1500	ratio	T081	C0456603
27782940	1502	1517	mean difference	T081	C0444504
27782940	1519	1521	MD	T081	C0444504
27782940	1534	1553	confidence interval	T081	C0009667
27782940	1555	1557	CI	T081	C0009667
27782940	1587	1596	decreased	T081	C0205216
27782940	1597	1601	Cl/F	T201	C1382187
27782940	1603	1605	MD	T081	C0444504
27782940	1617	1619	CI	T081	C0009667
27782940	1636	1641	Ob/ob	T015	C0025933
27782940	1656	1663	WT mice	T015	C1520150
27782940	1676	1684	increase	T169	C0442805
27782940	1688	1696	morphine	T109,T121	C0026549
27782940	1697	1705	exposure	T080	C0332157
27782940	1721	1727	AUC150	T081	C0376690
27782940	1729	1731	MD	T081	C0444504
27782940	1744	1746	CI	T081	C0009667
27782940	1763	1767	CMAX	T081	C2347813
27782940	1769	1771	MD	T081	C0444504
27782940	1782	1784	CI	T081	C0009667
27782940	1808	1812	T1/2	T079	C0018517
27782940	1814	1816	MD	T081	C0444504
27782940	1828	1830	CI	T081	C0009667
27782940	1857	1866	decreased	T081	C0205216
27782940	1867	1871	Cl/F	T201	C1382187
27782940	1873	1875	MD	T081	C0444504
27782940	1887	1889	CI	T081	C0009667
27782940	1915	1917	PK	T039	C0031327
27782940	1918	1928	parameters	T033	C0449381
27782940	1934	1947	significantly	T078	C0750502
27782940	1959	1964	ob/ob	T015	C0025933
27782940	1979	1987	DIO mice	T015	C0025933
27782940	1999	2005	AUC150	T081	C0376690
27782940	2007	2009	MD	T081	C0444504
27782940	2022	2024	CI	T081	C0009667
27782940	2041	2045	CMAX	T081	C2347813
27782940	2047	2049	MD	T081	C0444504
27782940	2060	2062	CI	T081	C0009667
27782940	2079	2083	T1/2	T079	C0018517
27782940	2085	2087	MD	T081	C0444504
27782940	2099	2101	CI	T081	C0009667
27782940	2119	2125	leptin	T116,T125	C0299583
27782940	2142	2152	ob/ob mice	T015	C0025933
27782940	2154	2156	PK	T039	C0031327
27782940	2157	2167	parameters	T033	C0449381
27782940	2186	2189	DIO	T015	C0025933
27782940	2194	2196	WT	T015	C1520150
27782940	2197	2203	levels	T080	C0441889
27782940	2205	2207	LR	T061	C0282402
27782940	2222	2227	ob/ob	T015	C0025933
27782940	2228	2232	mice	T015	C0025933
27782940	2237	2248	significant	T078	C0750502
27782940	2249	2258	decreases	T081	C0547047
27782940	2262	2268	AUC150	T081	C0376690
27782940	2270	2272	MD	T081	C0444504
27782940	2286	2288	CI	T081	C0009667
27782940	2308	2312	CMAX	T081	C2347813
27782940	2314	2316	MD	T081	C0444504
27782940	2328	2330	CI	T081	C0009667
27782940	2352	2356	T1/2	T079	C0018517
27782940	2358	2360	MD	T081	C0444504
27782940	2371	2373	CI	T081	C0009667
27782940	2391	2401	Metabolism	T040	C0025519
27782940	2402	2411	increased	T081	C0205217
27782940	2417	2419	LR	T061	C0282402
27782940	2426	2433	LR mice	T015	C0025929
27782940	2451	2454	M3G	T109,T121	C0066815
27782940	2460	2468	morphine	T109,T121	C0026549
27782940	2469	2474	ratio	T081	C0456603
27782940	2489	2492	DIO	T015	C0025933
27782940	2494	2496	MD	T081	C0444504
27782940	2507	2509	CI	T081	C0009667
27782940	2522	2538	Systemic effects	UnknownType	C0678788
27782940	2539	2554	associated with	T080	C0332281
27782940	2555	2562	obesity	T047	C0028754
27782940	2563	2571	decrease	T081	C0547047
27782940	2572	2580	morphine	T109,T121	C0026549
27782940	2581	2591	metabolism	T040	C0025519
27782940	2596	2605	excretion	T039	C0221102
27782940	2633	2643	laboratory	T073,T093	C0022877
27782940	2662	2669	obesity	T047	C0028754
27782940	2674	2691	leptin deficiency	T047	C3554224
27782940	2692	2700	decrease	T081	C0547047
27782940	2705	2716	sensitivity	T169	C0332324
27782940	2720	2755	central respiratory control centers	T022	C0460002
27782940	2759	2773	carbon dioxide	T123,T197	C0007012
27782940	2775	2782	Obesity	T047	C0028754
27782940	2787	2804	leptin deficiency	T047	C3554224
27782940	2819	2828	decreased	T081	C0205216
27782940	2829	2837	morphine	T109,T121	C0026549
27782940	2838	2848	metabolism	T040	C0025519
27782940	2853	2862	clearance	T201	C1382187
27782940	2868	2877	replacing	T169	C1299987
27782940	2878	2884	leptin	T116,T125	C0299583
27782940	2885	2895	attenuated	T052	C0599946
27782940	2900	2902	PK	T039	C0031327
27782940	2911	2926	associated with	T080	C0332281
27782940	2927	2944	leptin deficiency	T047	C3554224
27782940	2957	2963	leptin	T116,T125	C0299583
27782940	2977	2981	role	T077	C1705810
27782940	2985	2993	morphine	T109,T121	C0026549
27782940	2994	3004	metabolism	T040	C0025519